Pomalidomide Capsules

Multiple myeloma is a malignant disease characterized by abnormal proliferation of clonal plasma cells and is one of the common malignant tumors of the blood system. At present, the incidence of multiple myeloma in my country has exceeded that of acute leukemia, becoming the second most common malignant tumor of the blood system. As a third-generation immunomodulator, pomalidomide has shown unique anti-infection, immunomodulatory, anti-tumor proliferation, and anti-tumor angiogenesis effects, and has shown good efficacy and lower toxic side effects in clinical trials for refractory relapsed multiple myeloma.